Pulmonary embolism after dexamethasone treatment for COVID-19: a case report
Abstract Background Although the RECOVERY trial showed that dexamethasone was efficacious for the treatment of coronavirus disease 2019 (COVID-19), its impact on the risk of pulmonary embolism (PE) and other serious procoagulant events was not assessed. Case presentation Here we report the case of a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07228-2 |
| _version_ | 1811335330687614976 |
|---|---|
| author | Hidenori Takahashi Yoshinobu Iwasaki Takayasu Watanabe Naoki Ichinose Toshimi Oda |
| author_facet | Hidenori Takahashi Yoshinobu Iwasaki Takayasu Watanabe Naoki Ichinose Toshimi Oda |
| author_sort | Hidenori Takahashi |
| collection | DOAJ |
| description | Abstract Background Although the RECOVERY trial showed that dexamethasone was efficacious for the treatment of coronavirus disease 2019 (COVID-19), its impact on the risk of pulmonary embolism (PE) and other serious procoagulant events was not assessed. Case presentation Here we report the case of a previously healthy 83-year-old woman with COVID-19, without any genetic predisposition to thrombosis. She developed moderate respiratory distress 12 days after symptom onset and a 10-day course of dexamethasone therapy was initiated. Her clinical condition and imaging findings improved initially; however, they deteriorated after the completion of dexamethasone therapy, despite the improvement in her pneumonia and viral clearance. Laboratory tests showed markedly raised serum D-dimer, ferritin, and sIL-2R levels, and contrast-enhanced computed tomography showed deep vein thrombosis (DVT) in the left iliac vein and PE of the right pulmonary artery. The DVT and PE were successfully treated using intravenous heparin administration. Conclusions This case illustrates the potential risk of rebound inflammation and procoagulant events following dexamethasone withdrawal. We believe that COVID-19-induced DVT and PE can be affected by dexamethasone therapy. Although dexamethasone reduces procoagulant factors, increases anticoagulant factors, and modulates cytokines, which can suppress/delay thrombus formation during treatment, it confers the risk for rebound cytokine production after treatment completion, triggering cytokine and coagulation cascades that can lead to thromboembolic diseases. In this critical clinical period, the patient’s deteriorating condition may be overlooked because of the masking effects of dexamethasone treatment on fever and other clinical conditions and laboratory changes. Clinicians should follow-up coagulation markers carefully and contrast-enhanced computed tomography is useful for detecting coagulation; and, if PE occurs, therapeutic heparin administration is essential because emboli can also generate cytokines. |
| first_indexed | 2024-04-13T17:22:33Z |
| format | Article |
| id | doaj.art-af94603c904f42cd85662b762adb51a4 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-13T17:22:33Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-af94603c904f42cd85662b762adb51a42022-12-22T02:37:55ZengBMCBMC Infectious Diseases1471-23342022-03-012211510.1186/s12879-022-07228-2Pulmonary embolism after dexamethasone treatment for COVID-19: a case reportHidenori Takahashi0Yoshinobu Iwasaki1Takayasu Watanabe2Naoki Ichinose3Toshimi Oda4Department of Pulmonary Medicine, Showa General HospitalDepartment of Pulmonary Medicine, Showa General HospitalDepartment of Pulmonary Medicine, Showa General HospitalDepartment of Infection Control, Showa General HospitalDepartment of Infection Control, Showa General HospitalAbstract Background Although the RECOVERY trial showed that dexamethasone was efficacious for the treatment of coronavirus disease 2019 (COVID-19), its impact on the risk of pulmonary embolism (PE) and other serious procoagulant events was not assessed. Case presentation Here we report the case of a previously healthy 83-year-old woman with COVID-19, without any genetic predisposition to thrombosis. She developed moderate respiratory distress 12 days after symptom onset and a 10-day course of dexamethasone therapy was initiated. Her clinical condition and imaging findings improved initially; however, they deteriorated after the completion of dexamethasone therapy, despite the improvement in her pneumonia and viral clearance. Laboratory tests showed markedly raised serum D-dimer, ferritin, and sIL-2R levels, and contrast-enhanced computed tomography showed deep vein thrombosis (DVT) in the left iliac vein and PE of the right pulmonary artery. The DVT and PE were successfully treated using intravenous heparin administration. Conclusions This case illustrates the potential risk of rebound inflammation and procoagulant events following dexamethasone withdrawal. We believe that COVID-19-induced DVT and PE can be affected by dexamethasone therapy. Although dexamethasone reduces procoagulant factors, increases anticoagulant factors, and modulates cytokines, which can suppress/delay thrombus formation during treatment, it confers the risk for rebound cytokine production after treatment completion, triggering cytokine and coagulation cascades that can lead to thromboembolic diseases. In this critical clinical period, the patient’s deteriorating condition may be overlooked because of the masking effects of dexamethasone treatment on fever and other clinical conditions and laboratory changes. Clinicians should follow-up coagulation markers carefully and contrast-enhanced computed tomography is useful for detecting coagulation; and, if PE occurs, therapeutic heparin administration is essential because emboli can also generate cytokines.https://doi.org/10.1186/s12879-022-07228-2COVID-19SARS-CoV-2Pulmonary embolismAnticoagulationDexamethasoneCytokine |
| spellingShingle | Hidenori Takahashi Yoshinobu Iwasaki Takayasu Watanabe Naoki Ichinose Toshimi Oda Pulmonary embolism after dexamethasone treatment for COVID-19: a case report BMC Infectious Diseases COVID-19 SARS-CoV-2 Pulmonary embolism Anticoagulation Dexamethasone Cytokine |
| title | Pulmonary embolism after dexamethasone treatment for COVID-19: a case report |
| title_full | Pulmonary embolism after dexamethasone treatment for COVID-19: a case report |
| title_fullStr | Pulmonary embolism after dexamethasone treatment for COVID-19: a case report |
| title_full_unstemmed | Pulmonary embolism after dexamethasone treatment for COVID-19: a case report |
| title_short | Pulmonary embolism after dexamethasone treatment for COVID-19: a case report |
| title_sort | pulmonary embolism after dexamethasone treatment for covid 19 a case report |
| topic | COVID-19 SARS-CoV-2 Pulmonary embolism Anticoagulation Dexamethasone Cytokine |
| url | https://doi.org/10.1186/s12879-022-07228-2 |
| work_keys_str_mv | AT hidenoritakahashi pulmonaryembolismafterdexamethasonetreatmentforcovid19acasereport AT yoshinobuiwasaki pulmonaryembolismafterdexamethasonetreatmentforcovid19acasereport AT takayasuwatanabe pulmonaryembolismafterdexamethasonetreatmentforcovid19acasereport AT naokiichinose pulmonaryembolismafterdexamethasonetreatmentforcovid19acasereport AT toshimioda pulmonaryembolismafterdexamethasonetreatmentforcovid19acasereport |